We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Cognitive Function and Variability in Antipsychotic Drug–Naive Patients With First-Episode Psychosis: A Systematic Review and Meta-Analysis.
- Authors
Lee, Maria; Cernvall, Martin; Borg, Jacqueline; Plavén-Sigray, Pontus; Larsson, Cornelia; Erhardt, Sophie; Sellgren, Carl M.; Fatouros-Bergman, Helena; Cervenka, Simon
- Abstract
This systematic review and meta-analysis investigates cognitive function and variability before initiation of antipsychotic medication in patients with first-episode psychosis compared with controls. Key Points: Question: How do patients with first-episode psychosis (FEP) compare with controls in cognitive function and cognitive variability, before initiation of antipsychotic medication? Findings: In this systematic review and meta-analysis including 50 studies and 2625 individuals with FEP, the mean cognitive performance of antipsychotic drug–naive individuals with FEP was significantly impaired compared with controls, across all cognitive domains. At the same time, the within-group variability in FEP was significantly greater, indicating a wider distribution of cognitive ability in patients with FEP compared with controls. Meaning: Patients with psychosis display cognitive difficulties very early in the disease process, and the considerable heterogeneity in cognitive function should prompt individual assessments in clinical settings in order to optimize care. Importance: Cognitive impairment contributes significantly to clinical outcome and level of function in individuals with psychotic disorders. These impairments are present already at psychosis onset at a group level; however, the question of heterogeneity in cognitive function among patients has not been systematically investigated. Objective: To provide an updated quantification of cognitive impairment at psychosis onset before patients receive potentially confounding antipsychotic treatment, and to investigate variability in cognitive function compared with healthy controls. Data Sources: In this systematic review and meta-analysis, PubMed articles were searched up to September 15, 2022. Study Selection: Original studies reporting data on cognitive function in antipsychotic drug–naive patients with first-episode psychosis (FEP) were included. Data Extraction and Synthesis: Data were independently extracted by 2 researchers. Cognitive tasks were clustered according to 6 domains of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery and the domain of executive function. Random-effects model meta-analyses of mean differences and coefficient of variation ratios (CVRs) were performed, as well as meta-regressions, assessment of study quality, and publication bias. Main Outcomes and Measures: The main outcome measure was Hedges g for mean differences in cognition and CVR for within-group variability. Results: Fifty studies were included in the analysis with a total of 2625 individuals with FEP (mean [SD] age, 25.2 [3.6] years, 60% male; 40% female) and 2917 healthy controls (mean [SD] age, 26.0 [4.6]; 55% male; 45% female). In all cognitive domains, the FEP group displayed significant impairment compared with controls (speed of processing: Hedges g = −1.16; 95% CI, −1.35 to −0.98; verbal learning: Hedges g = −1.08; 95% CI, −1.28 to −0.88; visual learning: Hedges g = −1.05; 95% CI, −1.27 to −0.82; working memory: Hedges g = −1.04; 95% CI, −1.35 to −0.73; attention: Hedges g = −1.03; 95% CI, −1.24 to −0.82; reasoning/problem solving: Hedges g = −0.90; 95% CI, −1.12 to −0.68; executive function: Hedges g = −0.88; 95% CI, −1.07 to −0.69). Individuals with FEP also exhibited a larger variability across all domains (CVR range, 1.34-1.92). Conclusions and Relevance: Results of this systematic review and meta-analysis identified cognitive impairment in FEP before the initiation of antipsychotic treatment, with large effect sizes. The high variability within the FEP group suggests the need to identify those individuals with more severe cognitive problems who risk worse outcomes and could benefit the most from cognitive remediation.
- Subjects
COGNITIVE ability; COGNITIVE processing speed; COGNITION; COGNITIVE remediation; PSYCHOSES; VERBAL learning; SOMATIZATION disorder
- Publication
JAMA Psychiatry, 2024, Vol 81, Issue 5, p468
- ISSN
2168-622X
- Publication type
Article
- DOI
10.1001/jamapsychiatry.2024.0016